Fate Therapeutics, Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
5.4
Bearish
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
FATE
Clean balance sheet with low leverage (0.4× debt-to-equity).
⚠ low return on equity (-52%).
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
HOLD
Target $5.19 (+239.1%)
8 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
FATE
MRK
—
Trailing P/E
31.5×
-1.5×
Forward P/E
11.5×
0.0%
Profit Margin
13.6%
0.0%
Gross Margin
76.6%
-51.8%
ROE
—
-26.4%
Revenue Growth
4.9%
—
Earnings Growth
—
2.24
Beta
0.28
—
Price / Book
—
$178M
Market Cap
$277.0B
$1 – $2
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →